TrialCell reports. Medicine2024

Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer.

Matthew D Galsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.